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truncating alleles or affect residues that
are indispensable for PG transporter
activity, such as the missense muta-
tions c.763G4A (p.Gly255Arg) and
c.1668G4C (p.Gln556His) identified.
Both changes are nonconservative, affect
evolutionarily highly conserved amino
acids (Figure 2), and were predicted
in silico by all bioinformatic tools of
pathogenic relevance (Supplementary Ta-
ble 1 online). The pathogenic character
of c.763G4A (p.Gly255Arg) and the
impact of the glycine residue at position
255 is further strengthened by the fact
that the same codon was mutated
(c.764G4A; p.Gly255Glu) in a patient
described by Zhang et al. (2012). To
corroborate these data, we constructed
molecular models of wild-type and
mutated SLCO2A1 proteins to visualize
changes of protein folding and structure
(Meng et al., 2006; Bordoli et al., 2009;
Yang et al., 2011). Both mutations are
located in a transmembrane domain
and considerably affect the protein
structure (Figure 2), which was addi-
tionally confirmed by Ramachandran
plots (Supplementary Figure S1 online).
In this report, we show that
SLCO2A1 is a frequent cause of auto-
somal recessive PHO, confirming the
data recently published by Zhang et al.,
2012. Although most patients harbor
mutations in HPGD and SLCO2A1,
further genetic heterogeneity is likely,
and candidate approaches targeting
other PG-signaling components seem
promising.
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TO THE EDITOR
In atopic dermatitis (AD), lymphocytes
have an important role via regulation of
the immune response, production of
Igs, and sustaining cutaneous inflam-
mation.
In AD, activated T cells can be found
in blood, and most importantly in
affected skin a marked increase of
activated T cells is present (Akdis
et al., 2006). Serum levels of T-cell
chemokines CCL17 (thymus and activa-
tion regulated chemokine, TARC) and
Abbreviations: AD, atopic dermatitis; CsA, cyclosporine A; EC-MPS, enteric-coated mycophenolate
sodium; FUCT-VII, fucosyl transferase VII; MPA, mycophenolic acid; TARC, thymus and activation
regulated chemokine; TNF–AIP3, tumor necrosis factor–alpha inducible protein-3
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CCL27, as well as their receptors on T
cells, CCR4 and CCR10, are increased
in patients with AD and are correlated
with disease activity (Kakinuma et al.,
2001; Hijnen et al., 2004). In a
differential gene array analysis of CD4
cells, we demonstrated decreased ex-
pression of several genes related to
activation of regulation, such as tumor
necrosis factor–alpha inducible protein-
3 (TNF–AIP3), also named A20, and
GADD45a (Hijnen et al., 2005). A20
is considered a negative regulator of
inflammation (Sun, 2008). Decreased
A20 expression level in T cells in AD
patients may therefore be the primary
cause of the activated state of these
cells.
In patients with severe AD, treat-
ment with the calcineurin inhibitor
cyclosporine A (CsA) is effective. Re-
cently, mycophenolic acid (MPA), an
inhibitor of purine synthesis in both T
and B lymphocytes, has been used in
treatment of severe AD. In a recent
study, we have evaluated the clinical
effect of these immunosuppressive
drugs in AD (Haeck et al., 2011). After
a run-in on 5mg kg1 CsA, AD patients
were treated with 3mg kg1 CsA or
1,440mg enteric-coated mycopheno-
late sodium (EC-MPS) for 30 weeks.
Treatment resulted in reduction in
disease severity as determined by
SCORAD and serum TARC (CCL17)
levels. The aim of the current study
was to analyze the effect of treatment
of AD patients with CsA (n¼ 11) or
EC-MPS (n¼ 12) on immune cells to
relate clinical improvement with
immunological changes. Therefore, we
analyzed T and B cells at the level of
cell numbers, activation state, chemo-
kine receptors, skin-homing molecules,
and expression of FOXP3 and A20
in CD4þ T cells. Analyses were
performed during run-in, and during
study medication. CD4þ T-cell isola-
tion and mRNA analysis was performed
as described earlier (Hijnen et al.,
2005). In addition, 20 healthy nonaller-
gic controls were included for a single
leukocyte analysis. Differences be-
tween time points, as well as treatment
groups, were tested using a paired t-test
for normally distributed parameters and
a Wilcoxon signed-rank test for non-
normally distributed parameters.
During run-in and maintenance,
neither the percentage of CD3þ T cells
nor the percentage of CD4þ and CD8þ
within the CD3 population changed. In
addition, the distribution of memory
and naive CD4þ T cells, characterized
by CD45RO vs. CD45RA, remained
stable during treatment. In addition,
CD19þ B-cell percentages did not
change, nor was expression of the
activation marker CD69 altered on B
cells.
Expression of CCR10 and CCR4
mRNA did reduce during the run-in
period with 5mg kg1 CsA (P¼0.001
and 0.005 for CCR4 and CCR10,
respectively; Figure 1a and b). The
gene expression of fucosyl transferase
VII (FUCT-VII) followed a similar
pattern as the chemokine receptors
(Figure 1c).
Owing to the setup of the study, we
were unable to analyze functional
responses of the regulatory T cells.
Therefore, we used three different
markers, namely CD4þCD25high ex-
pression by flow cytometry, expression
of FOXP3 mRNA (data not shown), and,
for a limited group of patients, we
analyzed FoxP3 protein expression in
the CD4þT cells (Figure 2a and b).
Already at the 3-week run-in time
point, there was a maximal decrease
for all markers. There was no effect on
the expression of A20 in both treatment
regimes (see Figure 2c and d).
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Figure 1. Changes in skin-homing marker expression. Relative mRNA levels were determined for
CCR10 (a), CCR4 (b), and fucosyl transferase VII (FUCT-VII, c). Relative expression is determined
as described in Materials and Methods. The horizontal line depicts the expression level in 20
nonallergic controls. These control values were CCR10 19.8±2.6/HKG; CCR4 4.69±0.4/HK0G; and
FUT7 31.9±6.4/HKG. O, cyclosporine A; D, enteric-coated mycophenolate sodium. Data are shown
as mean±SEM.
www.jidonline.org 2477
EF Knol et al.
Lymphocyte Function in Atopic Dermatitis
In this study, we showed that the
clinically successful treatment of severe
AD with CsA or EC-MPS results in
selective changes in lymphocyte para-
meters. Already during the run-in phase
with 5mg kg1 CsA, the reduction
of skin-homing markers and regulatory
T-cell (Treg) markers was achieved.
This reduction was further sustained
during the maintenance period with
3mg kg1 CsA and EC-MPS.
The decrease in the three skin
homing–related markers in CD4þ T
cells indicates that during treatment
peripheral blood T cells have a dimin-
ished capacity to enter the skin. Inter-
estingly, when we analyzed changes in
CCR8, related to Th2-type inflamma-
tion, and CXCR3, related to Th1-type
inflammation (Islam et al., 2011), we
found a more delayed (tX6 weeks, after
randomization) or no decrease for
CCR8 and CXCR3, respectively (data
not shown). This indicates that the
changes in CCR4, CCR10, and FUCT-
VII are directly linked to the clinical
improvement.
The markers for Tregs change in a
manner similar to the clinical score of
the eczema and serum TARC levels of
the patients. In vitro, CsA inhibits Treg
promoter activity (Mantel et al., 2006).
On the other hand, in another study, it
was found that neither CsA nor MPA
has an effect on the expression of Treg
transcription marker FOXP3 (Abadja
et al., 2009). In our view, it is more
likely that the decreased Treg levels
are due to decreased inflammatory
signals by treatment with CsA and
EC-MPS. Unfortunately, we were
not able to test the functional capacity
of this Treg population, which is
important.
No increase in the expression of A20
was shown, although the patients’
condition clinically improved. One of
the explanations is that A20 expression
is not related to AD severity, but that its
expression is more upstream in the
regulation of T cells, as it is supposed
to be important in several chronic
inflammatory diseases (Elder et al.,
2010). A20 is involved in termination
of NF-kB signaling. Therefore, we
checked the expression of lymphotox-
in-alpha, which is involved in
NF-kB activation (Schneider et al.,
2004), and could not find a changed
expression (not shown). Another
A20 family member is Sezanne
(Ruland, 2011). Its expression was also
not changed during treatment (not
shown).
We conclude that treatment of
patients with severe AD with drugs
affecting lymphocytes have selective
effects on lymphocytes. Mainly the
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Figure 2. Expression of markers of regulation during treatment. The amount of regulatory T-cell markers was quantified at the level of FOXP3
protein expression in CD4þ lymphocytes determined by flow cytometry during cyclosporine A (CsA) treatment (a) and during enteric-coated
mycophenolate sodium (EC-MPS) treatment (b). Expression of A20/tumor necrosis factor–alpha inducible protein-3 (TNF–AIP3) mRNA expression
in CD4þ T cells during CsA treatment (c) and during EC-MPS treatment (d). Each symbol depicts the determination in an individual patient, and the
horizontal mark depicts the median. The horizontal line depicts the expression level in 20 nonallergic controls. O, CsA; D, EC-MPS. MPA, mycophenolic
acid.
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is diminished, limiting the potency of
T cells to enter skin sites. On the other
hand, the decrease in Treg markers
might be the result of decreased in-
flammation, and together with the
persistent decreased expression of
A20/TNF–AIP3 might be important for
the only transient improvement often
seen after CsA treatment.
The study was approved by the
local ethics committee and patients
gave their written informed consent.
This study was conducted accord-
ing to the Declaration of Helsinki
Principles.
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TO THE EDITOR
Epidermal melanocytes (MCs) are
specialized melanin-producing cells
(Slominski et al., 2004; Yamaguchi
et al., 2007; Thomas and Erickson,
2008; Park et al., 2009) that synthesize
melanin within the melanosome
(Slominski et al., 2004) and protect
individuals from harmful UV rays
(Slominski et al., 2004; Yamaguchi
et al., 2007; Thomas and Erickson,
2008; Park et al., 2009). Defects in or
a lack of MCs can lead to melanoma,
pigment disorders, and auditory de-
fects. MC proliferation and differentia-
tion in skin is tightly linked to hair
regeneration cycles. MCs in vertebrates
are derived from neural crest (Thomas
and Erickson, 2008). In hair follicles,
melanoblasts are segregated into hair
matrix MCs (for hair pigmentation) and
melanocyte stem cells (MCSCs). The
discovery of MCSCs and induced plur-
ipotent (iPS) cells provides important
resources to elucidate mechanisms
underlying melanogenesis and patho-
genesis of MC-related disorders (Lin
and Chuong, 2011; Nishikawa-Torikai
et al., 2011; Nishimura, 2011; Ohta
et al., 2011; Yang et al., 2011).
Although MCSCs and iPS cells are
important MC precursors for mechan-
istic studies, their isolation and expan-
sion are technically challenging.
Here we investigate whether MCs
can be immortalized without com-
promising melanogenic potential. By
using primary MCs isolated from
newborn mouse skin, we engineered
4100 clones by introducing SV40 T
antigen (SV40T), which is flanked with
FRT sites (Supplementary Figure S1A
online; Westerman and Leboulch,
1996). We found that although primary
MCs grew slower after passage 5
immortalized MC (iMC) cells acquired
Abbreviations: FLP, flippase recombination enzyme; GFP, green fluorescent protein; GLuc, Gaussia
luciferase; iMC, immortalized melanocyte; iPS, induced pluripotent; MCSC, melanocyte stem cell;
TRP-1, tyrosinase-related protein 1
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Melanogenesis of Immortalized Melanocytes
